In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Increasingly Specialist Focus

Executive Summary

Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,

Related Content

Bristol-Myers's Grand Ambitions in Oncology
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Collaborating for Better R&D Productivity
GSK Tries to Mimic Real-World Biotech
Biopharma in 2008: What a Difference an Economic Crisis Makes
Pfizer Restructures for a More Flexible Future
Takeda's Global Ambition
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
How Big Pharma is Tackling the R&D Problem


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts